We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
T2 Biosystems Inc | NASDAQ:TTOO | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.07 | 2.55% | 2.81 | 2.70 | 2.90 | 2.9353 | 2.7001 | 2.76 | 140,888 | 01:00:00 |
At the symposium, leading experts from several U.S. and European hospitals will discuss how the FDA-cleared and CE-marked T2Candida Panel is delivering significant improvements in patient outcomes in conjunction with substantial economic savings. In addition, early performance data from T2Bacteria Panel and our sepsis product pipeline will be shared, highlighting the promise to deliver the same significant benefits of rapid and highly sensitive direct-from-blood detection as T2Candida.
Chair: Maurizio Sanguinetti, MD, Policlinico Universitario Agostino Gemelli, Rome, Italy
Presentations: Proven Clinical Benefit and Economic Savings of T2Candida in Hospital Practice Sandy J. Estrada, Pharm.D., BCPS, Lee Health System, Florida, USA
T2Candida – Impactful Case Study Reviews Patricia Muñoz, MD, PhD, Hospital General Universitario Gregorio Marañón, Madrid, Spain
Early Experience with T2Bacteria - Direct-from-Blood Species Identification Giulia De Angelis, MD, Policlinico Universitario Agostino Gemelli, Rome, Italy
The Future of Rapid, Direct-from-Blood Sepsis Diagnostics Rahul Dhanda, T2 Biosystems, Massachusetts, USA
Date/Time/Location Saturday 22 April 2017 13:30 - 15:30pm Reed Messe Wien GmbH (HALL C) Messeplatz 1, Postfach 277 A-1021 Wien
Be sure to follow all T2 specific developments and news from the #ECCMID2017 conference on Twitter via the T2 Biosystems handle @T2Bio.
Media interested in one-on-one interviews live or by phone before or after the T2 symposium should contact the T2 press coordinators below to set up an interview.
Click here for highlights of IDWeek 2016 hospital data detailing improvements in patient care and hospital savings from T2Candida.
In addition, T2 Biosystems will be presenting a poster on the T2Lyme Panel:
P0342. “Direct detection of early-stage Lyme borreliosis using T2 magnetic resonance”Session: Challenges in diagnostic bacteriologyPresenter: T2 BiosystemsDate: Saturday, 22 April 2017
About T2 BiosystemsT2 Biosystems is focused on developing innovative diagnostic products to improve patient health. With the FDA-cleared T2Dx® Instrument and T2Candida Panel targeting sepsis and a range of additional products in development, T2 Biosystems is an emerging leader in the field of in vitro diagnostics. The Company is utilizing its proprietary T2 Magnetic Resonance platform, or T2MR®, to develop a broad set of applications aimed at lowering mortality rates, improving patient outcomes and reducing the cost of healthcare by helping medical professionals make targeted treatment decisions earlier. T2MR enables the fast and sensitive detection of pathogens, biomarkers and other abnormalities in a variety of unpurified patient sample types, including whole blood, eliminating the time-consuming sample prep required in current methods. For more information, please visit www.t2biosystems.com.
Media Contacts: Amy Crosby, T2 Biosystems acrosby@t2biosystems.com +1 (978) 478-8451 On-site contact Matthew McKillip, T2 Biosystems mmckillip@t2biosystems.com +1 (518) 577-3466 Investor Contact: Tucker Elcock, Teneo Strategy Tucker.Elcock@teneostrategy.com +1 (212) 886-9319
1 Year T2 Biosystems Chart |
1 Month T2 Biosystems Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions